



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re Application of:**

Houtzager et al.

**Serial No.:** 10/016,516

**Filed:** December 10, 2001

**For:** A STRUCTURE FOR PRESENTING  
DESIRED PEPTIDE SEQUENCES

**Confirmation No.:** 8313

**Examiner:** T. Wessendorf

**Group Art Unit:** 1639

**Attorney Docket No.:** 2183-5208US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV325784280US

Date of Deposit with USPS: November 24, 2003

Person making Deposit: Christopher Haughton

RECEIVED  
DEC 03 2003  
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in

Serial No.: 10/016,516

37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
US 2002019517 A1	02-14-2002	Koide

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
WO 99 16873	04-08-1999	A. Skerra
WO 98 56915	12-17-1998	Research Corp. Technologies, Inc.
WO 01 64942	09-07-2001	Phylos Inc.
WO 00 60070	10-12-2000	Innogenetics NV
EP 1 318 195 A1	06-11-2003	CatchMabs BV

Other Documents

European Search Report, EP 01 20 4762, 2 pages.

SKERRA, 'Anticalins': a new class of engineered ligand-binding proteins with antibody-like properties, Reviews in Molecular Biotechnology , 2001, pp. 257-75, Vol. 74, No. 4.

SCHLEHUBER et al., Duocalins: Engineered Ligand-Binding Proteins with Dual Specificity Derived from the Lipocalin Fold, September 2001, pp. 1335-42, Vol. 382.

**Serial No.: 10/016,516**

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming a common inventor:

Attorney Docket No.: 2183-5610US  
Serial No.: 10/316,194  
Filing Date: 12/10/2002  
Title: A STRUCTURE FOR PRESENTING DESIRED PEPTIDE SEQUENCES

Attorney Docket No.: 2578-5808US  
Serial No.: 10/382,361  
Filing Date: 3/5/2003  
Title: HEAVY CHAIN LIBRARIES

Attorney Docket No.: 2183-5611US  
Serial No.: 60/432,906  
Filing Date: 12/10/2002  
Title: AFFINITY PROTEINS FOR CONTROLLED APPLICATION OF COSMETIC SUBSTANCES

Attorney Docket No.: 2183-5979US  
Serial No.: 60/467,514  
Filing Date: 5/2/2003  
Title: REDUCING VIRUS LOAD IN AIR STREAMS

Serial No.: 10/016,516

This Information Disclosure Statement is believed to be filed before the mailing date of a first Office Action on the merits; therefore, no fee is due.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Allen C. Turner', with a long horizontal flourish extending to the right.

Allen C. Turner

Registration No. 33,041

Attorney for Applicant(s)

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: November 14, 2003

ACT/bv

Enclosures: Form PTO-1449 or PTO/SB/08

Cited Documents

Document in ProLaw

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet

of

**Complete if Known**

Application Number	10/016,516
--------------------	------------

Filing Date	December 10, 2001
-------------	-------------------

First Named Inventor	Houtzager et al.
----------------------	------------------

Group Art Unit	1639
----------------	------

Examiner Name	T. Wessendorf
---------------	---------------

Attorney Docket Number	2183-5208US
------------------------	-------------

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		WO 99 16873	04-08-1999	A. Skerra		
		WO 98 56915	12-17-1998	Research Corp. Technologies, Inc.		
		WO 01 64942	09-07-2001	Phylos Inc.		
		WO 00 60070	10-12-2000	Innogenetics NV		
		EP 1 318 195 A1	06-11-2003	CatchMabs BV		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

of

**Complete if Known**

Application Number	10/016,516
Filing Date	December 10, 2001
First Named Inventor	Houtzager et al.
Group Art Unit	1639
Examiner Name	T. Wessendorf
Attorney Docket Number	2183-520811S

**RECEIVED**  
DEC 23 2003  
TECH CENTER 1600/2900**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		European Search Report, EP 01 20 4762, 2 pages.	
		SKERRA, 'Anticalins': a new class of engineered ligand-binding proteins with antibody-like properties, Reviews in Molecular Biotechnology, 2001, pp. 257-75, Vol. 74, No. 4.	
		SCHLEHUBER et al., Duocalins: Engineered Ligand-Binding Proteins with Dual Specificity Derived from the Lipocalin Fold, September 2001, pp. 1335-42, Vol. 382.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.